NewKerala.com

India Steps Up Scrutiny of Weight-Loss Drugs Amid Safety, Misuse Fears

The Indian Pharmacopoeia Commission has begun regular monitoring of adverse events linked to weight-loss drugs through the national pharmacovigilance system. This move coincides with the Drug Controller General of India intensifying regulatory action against the unauthorized sale and promotion of these GLP-1 based medications. Authorities have issued a comprehensive advisory to manufacturers and conducted inspections at 49 businesses, including online pharmacies and clinics, focusing on prescription violations and misleading marketing. The government warns of continued strict surveillance, with penalties including license cancellation and legal action for rule-breakers.

Key Points: India Monitors Weight-Loss Drug Safety, Cracks Down on Misuse

  • IPC monitoring GLP-1 drug safety
  • DCGI issues advisory against misleading ads
  • 49 businesses inspected nationwide
  • Stricter surveillance and legal action promised
2 min read

Indian Pharmacopoeia Commission (IPC) regularly monitoring adverse events of weight-loss drugs

IPC and DCGI intensify surveillance of GLP-1 drugs, inspect 49 businesses, and issue warnings to curb unauthorized sales and misleading ads.

"IPC is regularly monitoring the adverse events of such drugs through the passive surveillance system under PvPI. - Official sources"

By Shalini Bhardwaj, New Delhi, April 4

The Indian Pharmacopoeia Commission, which acts as the National Coordination Centre for the Pharmacovigilance Programme of India and provides evidence-based research to CDSCO, will be monitoring the safety of weight loss drugs. The Indian Pharmacopoeia Commission will be compiling a report of adverse events which are associated with the GLP-1 drugs.

According to the Official sources, the IPC has started the regular monitoring of adverse events of weight-loss drugs through the PvPI system: "IPC is regularly monitoring the adverse events of such drugs through the passive surveillance system under PvPI."

The official further said that they will be interacting regularly with the manufacturers to monitor the safety of such drugs, "We are also going to organise regular interaction with the manufacturers to monitor the safety of such drugs actively."

After several reports filed by the ANI regarding misleading advertisements and misuse of weight loss drugs, the Drug Controller General of India has intensified its regulatory surveillance against the unauthorised sale and promotion of the drugs.

To ensure that people do not take GLP-1 drugs without a medical prescription and to curb malpractices, the Drug Controller General of India, in collaboration with State Drug Controllers, took the following actions.

"On 10th March 2026, a comprehensive advisory was issued to all drug manufacturers to stop misleading advertisements and any promotion that could encourage people to use GLP-1 drugs without a prescription." Stated Union Ministry of Health and Family Welfare in a release

"In recent weeks, 49 businesses were audited and inspected across the country, including online pharmacy warehouses, drug wholesalers, retailers, and weight loss clinics. These inspections spanned multiple regions across India and focused on identifying violations related to unauthorised sale, improper prescription practices, and misleading marketing. Notices have been issued to those found breaking the rules." Its said

It said further, "Stricter inspections and surveillance will continue in the coming weeks. Businesses that break the rules will face license cancellation, fines, and legal action."

- ANI

Share this article:

Reader Comments

R
Rohit P
Finally! The crackdown on online pharmacies and clinics is long overdue. My cousin ordered some pills online without a prescription and had severe side effects. These regulations must be enforced strictly across all states.
D
David E
Good to see proactive pharmacovigilance. In many Western countries, post-market surveillance for such drugs is robust. India building a similar evidence-based system through PvPI is a positive move for public health.
A
Ananya R
While monitoring is good, I hope the focus is also on creating awareness. People need to understand that these are serious prescription drugs, not lifestyle supplements. The "quick fix" mentality is dangerous.
V
Vikram M
Inspecting 49 businesses is a start, but the network is huge. I respectfully question if the regulatory manpower is sufficient for nationwide surveillance. Hope the action is sustained and not just a temporary drive.
S
Shreya B
This is so necessary. The pressure to look a certain way, especially on young people, is immense. These drugs are being glamorized by influencers. Health should come first, always. Thank you, IPC and CDSCO. 🙏

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50